A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s...
MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology...
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied dosesWALTHAM,...
Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months...
-- The United States FDA Clears Initiation of Efficacy Trial in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Patients A Phase...
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy...
The Site Initiation Visit for the BWH clinical staff is complete and a shipment of LIBERTY investigational units was deliveredBRAINTREE,...
~ Emphasizes Strong Cash Position, No Debt, and A Dedicated Management Team Focused on Delivering Growth and Value to Shareholders...
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71%...
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses...
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional...
LAVAL, QC / ACCESSWIRE / June 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company enriching...
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few...
$6 million upfront with up to an additional $18 million of aggregate gross proceeds upon the exercise in full of...
Clinical trials for AI Nose-powered Ainos Flora device moves forward with 75 meaningful case results, paving the way for next-gen...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into...
Partner’s software products and services are utilized by hundreds of life science organizations, including the top 30 biopharmaceutical companiesMINNEAPOLIS, June...
Vivalink's survey reveals strong consumer support for flexible care models, indicating a need for home based care as part of...
LAS VEGAS, June 13, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and...
With the FDA 510(k) clearance of the COR-12 wireless ECG device now integrated with the SpiroSphere®, sponsors can conduct comprehensive...